Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $14,502.00 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $193.36, for a total transaction of $14,502.00. Following the sale, the executive vice president owned 16,580 shares of the company’s stock, valued at $3,205,908.80. This trade represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Michael Feld also recently made the following trade(s):

• On Monday, October 27th, Michael Feld sold 57 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $186.01, for a total transaction of $10,602.57.
• On Friday, September 26th, Michael Feld sold 58 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $181.03, for a total value of $10,499.74.

Becton, Dickinson and Company Trading Up 0.1%

Shares of BDX opened at $193.68 on Friday. The stock has a 50 day simple moving average of $188.09 and a 200-day simple moving average of $183.61. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The stock has a market cap of $55.28 billion, a PE ratio of 33.22, a PEG ratio of 1.79 and a beta of 0.25. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 71.36%.

Analysts Set New Price Targets

Several analysts recently commented on the company. Stifel Nicolaus dropped their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday, November 7th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday. Argus increased their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Jefferies Financial Group cut their target price on Becton, Dickinson and Company from $257.00 to $215.00 in a research note on Friday, November 7th. Finally, Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $204.45.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. SOA Wealth Advisors LLC. grew its position in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares during the last quarter. Activest Wealth Management grew its stake in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 97 shares during the period. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter worth approximately $25,000. Saudi Central Bank bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $26,000. Finally, Bell Investment Advisors Inc grew its position in Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.